The future of clinical trials evaluating blood substitutes

Editorial

Dean A Fergusson et al. JAMA. 2008.

. 2008 May 21;299(19):2324-6.

doi: 10.1001/jama.299.19.jed80027. Epub 2008 Apr 28.

No abstract available

Comment in

Hemoglobin-based blood substitutes and risk of myocardial infarction and death.
Keipert PE, Olofsson C, Winslow RM. Keipert PE, et al. JAMA. 2008 Sep 17;300(11):1295-6; author reply 1298-9. doi: 10.1001/jama.300.11.1295-b. JAMA. 2008. PMID: 18799435 No abstract available.
Hemoglobin-based blood substitutes and risk of myocardial infarction and death.
Levien LJ, Hodgson RE, James MF. Levien LJ, et al. JAMA. 2008 Sep 17;300(11):1295; author reply 1298-9. doi: 10.1001/jama.300.11.1295-a. JAMA. 2008. PMID: 18799436 No abstract available.
Hemoglobin-based blood substitutes and risk of myocardial infarction and death.
Sarani B, Gracias V. Sarani B, et al. JAMA. 2008 Sep 17;300(11):1297-8; author reply 1298-9. doi: 10.1001/jama.300.11.1297-b. JAMA. 2008. PMID: 18799439 No abstract available.
Hemoglobin-based blood substitutes and risk of myocardial infarction and death.
Sauaia A, Moore EE, Banerjee A. Sauaia A, et al. JAMA. 2008 Sep 17;300(11):1297; author reply 1298-9. doi: 10.1001/jama.300.11.1297-a. JAMA. 2008. PMID: 18799440 No abstract available.

Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis.
Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. Natanson C, et al. JAMA. 2008 May 21;299(19):2304-12. doi: 10.1001/jama.299.19.jrv80007. Epub 2008 Apr 28. JAMA. 2008. PMID: 18443023 Free PMC article.